Product Description
BAY 1251152 (BAY) is a potent and highly selective second generation PTEFb/CDK9 inhibitor.
Mechanisms of Action: CDK9 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Hematological Unspecified|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT02745743 | P1 |
Completed |
Oncology Hematological Unspecified|Oncology Unspecified |
2018-08-03 |
4% |
2019-03-22 |
Treatments |